Cagrilintide and CJC-1295 with DAC Interaction

Synergistic
Mechanism-based 51% confidence

Cagrilintide and CJC-1295 with DAC have a synergistic interaction with 51% confidence. Cagrilintide helps counteract the insulin-disrupting effects of CJC-1295 with DAC. A smart combination — the insulin sensitizer mitigates metabolic side effects. Both compounds affect the gi tract, so monitoring these systems is recommended.

Compound Profiles

Cagrilintide

Long-Acting Amylin Receptor Agonist | Weight Loss & Diabetes

Subcutaneous injection enables optimal bioavailability, targeting dual amylin and calcitonin receptors for satiety and metabolic regulation. Enhances insulin sensitivity and controls gastric emptying.

Half-life: ~7 days (159-195 hours) Typical dose: 2.4mg weekly (after escalation) weight loss, metabolic
amylin receptor cardiotoxicinsulin sensitizing
View full profile

CJC-1295 with DAC

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation..

Half-life: 6-8 days Typical dose: 1-2mg weekly growth hormone, weight loss
ghrh receptorigf1 carcinogenic riskestrogenicinsulin disrupting
View full profile

Combined Organ Load

GI Tract
low
Pancreas
low
Pituitary
low

Frequently Asked Questions

Can I take Cagrilintide with CJC-1295 with DAC?

Yes, Cagrilintide and CJC-1295 with DAC can generally be taken together. Cagrilintide helps counteract the insulin-disrupting effects of CJC-1295 with DAC. A smart combination — the insulin sensitizer mitigates metabolic side effects.

Is Cagrilintide and CJC-1295 with DAC safe together?

Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.

What are the interactions between Cagrilintide and CJC-1295 with DAC?

Cagrilintide helps counteract the insulin-disrupting effects of CJC-1295 with DAC. A smart combination — the insulin sensitizer mitigates metabolic side effects. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time Cagrilintide and CJC-1295 with DAC?

Cagrilintide has a half-life of ~7 days (159-195 hours) and CJC-1295 with DAC has a half-life of 6-8 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Cagrilintide vs CJC-1295 with DAC

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.